Neuraxis (NRXS) director issued 13,157 shares at $2.85

Neuraxis, Inc. (NRXS) director Jane Elizabeth Keyser received 13,157 shares of common stock as compensation for board service.

Rhea-AI Filing Summary

Neuraxis, Inc. (NRXS) director Jane Elizabeth Keyser received 13,157 shares of common stock as compensation for board service. The transaction was executed on 01/17/2025 at a reported price of $2.85 per share, leaving the reporting person with 24,737 shares beneficially owned following the issuance. The Form 4 identifies Keyser as a director and the shares were issued specifically as independent director compensation. The filing is signed by Beth Keyser on 09/10/2025 and includes the reporting person’s address in Carmel, Indiana.

Positive

• Transparent disclosure of a director equity grant including date, price, and resulting beneficial ownership
• Equity compensation aligns the independent director’s interests with shareholders as stated in the filing
• Form 4 includes signature and explanatory note clarifying shares were issued for services

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Director received equity as compensation, aligning pay with shareholder interests but not a material corporate event.

This Form 4 documents a routine equity grant to an independent director for services rendered. Issuing 13,157 shares at $2.85 each increases the director’s stake to 24,737 shares and is presented as compensation rather than a purchase. From a governance standpoint, equity compensation for non-employee directors is common and can help align incentives with shareholders; the filing provides clear disclosure of the award and resulting ownership.

Securities Compliance Analyst

TL;DR: Disclosure appears complete for the reported issuance; no derivative transactions or other complexities disclosed.

The Form 4 lists only a non-derivative issuance on 01/17/2025 and includes an explicit explanatory note that the shares were issued for director services. There are no reported option exercises, dispositions, or indirect ownership notations. The filing includes the reporting person’s relationship to the issuer and a manual signature, satisfying routine Section 16 reporting elements.

Insider Trade Summary

Grant/Award: 13,157 shares

Grant/Award 1 txn

Insider Keyser Jane Elizabeth

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	13,157	$2.85	$37K

Holdings After Transaction: Common Stock — 24,737 shares (Direct)

Footnotes (1)

1. F1. These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Jane Elizabeth Keyser report on the Form 4 for NRXS?

The Form 4 reports an issuance of 13,157 shares of Neuraxis common stock on 01/17/2025 at a reported price of $2.85 per share.

How many Neuraxis (NRXS) shares does the reporting person own after the transaction?

The reporting person beneficially owned 24,737 shares following the reported transaction.

Why were the shares issued to the reporting person?

The filing states the shares were issued to the reporting person as compensation for services as an independent director.

Does the Form 4 show any option exercises or derivative transactions for NRXS?

No. The filing lists only a non-derivative issuance of common stock and contains no derivative securities or option exercises.

Who signed the Form 4 for this reporting person?

The Form 4 is signed by /s/ Beth Keyser with a signature date of 09/10/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/10/2025 - 06:32 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Keyser Jane Elizabeth

(Last) (First) (Middle)

11611 N. MERIDIAN ST, SUITE 330

(Street)

CARMEL IN 46032

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Neuraxis, INC [ NRXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/17/2025		A		13,157	A	$2.85(1)	24,737	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

	/s/ Beth Keyser	09/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.